Company: CRVO
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001437749-25-013543
Chunk: 52

Company: CervoMed Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 52
---
     |      Average 
      Summary 
 Compensation 
  Table Total 
  for Non-PEO 
  NEOs (1)(2) |     |      Average 
 Compensation 
     Actually 
 Paid to Non- 
     PEO NEOs 
       (1)(2) |     |       Value 
          of 
     Initial 
       Fixed 
        $100 
  Investment 
       Based 
          On 
       Total 
 Shareholder 
      Return 
         (3) |     | Net       
 Income    
 (Loss)    
 (in       
 millions) 
 (4)       |
| 2022 |     |   $1,424,613 |     |     $1,302,245 |     |     $400,727 |     |     $318,800 |     |      $32.65 |     | $(5.80)   |
| 2023 |     |   $1,518,279 |     |     $1,366,539 |     |     $467,047 |     |     $457,134 |     |      $32.82 |     | $(2.17)   |
| 2024 |     |   $1,036,352 |     |       $953,313 |     |     $732,491 |     |     $797,375 |     |      $10.06 |     | $(16.29)  |

| (1) | On August 16, 2023, in connection with the completion of the Merger, the Company’s executive officers were reconstituted. At the Effective Time of the Merger, (i) Dr. Alam, the President & Chief Executive Officer of EIP, was appointed as the Company’s President & Chief Executive Officer, (ii) Dr. Cobuzzi, the President & Chief Executive Officer of Diffusion, was appointed as the Company’s Chief Operating Officer, and (iii) Mr. Elder, the General Counsel & Corporate Secretary of Diffusion, continued as the Company’s General Counsel & Corporate Secretary. Mr. Elder was subsequently appointed as the Company’s Chief Financial Officer in June 2024. Accordingly, (x) the amounts set forth in the table with respect to PEO compensation include, (i) with respect to the years ended December 31, 2023 and 2022, compensation paid to Drs. Alam and Dr. Cobuzzi, and (ii) with respect to the year ended December 31, 2024